RecruitingNot ApplicableNCT06272136
Liom Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM)
An Exploratory Study to Assess the Accuracy in the Normo- to Hyperglycemic Range of the Spiden Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM), in Trial Participants with Type 1 or Type 2 Diabetes
Sponsor
Liom Health AG
Enrollment
80 participants
Start Date
Feb 23, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This is a single-centre, multiple cohort, open study.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria3
- Male or female trial participant with clinically diagnosed type 1 or type 2 diabetes for at least 1 year.
- Age between 18 and 65 years, both inclusive.
- Treated with insulin and/or oral antidiabetic drugs (OADs; type 2 only), multiple dosing insulin therapy (MDI), continuous subcutaneous insulin infusion (CSII) or a hybrid closed loop system.
Exclusion Criteria3
- Known or suspected hypersensitivity to any of the components of the Liom Clinical Demo 2.0.
- Trial participant with any injury, infection, atypical skin condition (e.g., hyperkeratosis, hyperpigmentation) of or tattoo on the wrists.
- Presence or history of a cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, transient ischaemic attack, stroke, cardiac decompensation, clinically significant arrhythmias or clinically significant conduction disorders.
Interventions
DEVICEClinical Demo 2.0
During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06272136
Related Trials
Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients
NCT063246044 locations
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
NCT060148791 location
Intervention for Children With Type 1 Diabetes Targeting Gut Microbes
NCT061987251 location
Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery
NCT072121791 location
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
NCT0706157411 locations